The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling is a research paper published in Neuro-Oncology Advances (2020). On theSindex it has a DataRank of 0.606. It has been cited 56 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.606
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: RO1CA190223
NCI NIH HHS
Grant: R01 CA190223
NCI NIH HHS
Grant: R01 CA226765
NCI NIH HHS
Grant: R01 CA229451
NINDS NIH HHS
Grant: R01 NS103927
National Institutes of Health
Grant: 5R01CA190223-09
Optimizing demethylating therapy for IDH1 Mutant Malignant Gliomas
National Institutes of Health
Grant: 5R01NS103927-03
Novel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastoma
Virginia and D.K. Ludwig Fund for Cancer Research
FWCI
3.37
Citation Percentile
0.9%
Influential Citations
1
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals